Cytokine storm (CS), or hypercytokinemia, represents an uncontrolled immune response characterized by excessive release of pro-inflammatory cytokines such as IL-6 (Interleukin), IL-1β, Tumor necrosis factor-alpha (TNF-α), and Interferon (IFN-γ). While originally described in graft-versus-host disease and viral infections, recent evidence highlights its crucial role in metabolic disorders, including obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD/NASH). At the molecular level, CS arises from activation of pattern recognition receptors, inflammasome signaling, and JAK-STAT (Janus Kinase (JAK) / Signal Transducer and Activator of Transcription (STAT) pathways, amplified by immune and metabolic cell interactions. In obesity, adipocyte hypertrophy induces hypoxia and macrophage recruitment, forming crown-like structures that perpetuate low-grade inflammation and insulin resistance. In T2DM, hyperglycemia and oxidative stress exacerbate cytokine-driven β-cell dysfunction and apoptosis. In NAFLD/NASH, Kupffer cell activation and cytokine cross-talk with hepatic stellate cells promote fibrosis. Moreover, gut microbiota dysbiosis facilitates endotoxemia and TLR4-mediated cytokine release, aggravating systemic inflammation. Circulating cytokines serve as diagnostic and prognostic biomarkers and guide therapeutic monitoring, with potential for precision medicine approaches. Targeting cytokine and TLR pathways offers promising strategies to mitigate inflammation-driven metabolic disease progression and improve clinical outcomes.